{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:40:59Z","timestamp":1758814859892},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,2,15]]},"abstract":"<jats:p> PURPOSE: The primary objective of this phase I trial was to determine the feasibility of administering a combination of paclitaxel, cisplatin, and doxorubicin with or without granulocyte colony-stimulating factor (G-CSF) in patients with advanced endometrial and other gynecologic cancers. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients were chemotherapy-naive. Doxorubicin was administered as a brief infusion, paclitaxel for 3 hours, and cisplatin for 60 minutes. Treatments were repeated every 3 weeks. For most dose levels, the cisplatin and doxorubicin were fixed at 60 mg\/m<jats:sup>2<\/jats:sup> and 45 mg\/m<jats:sup>2<\/jats:sup>, whereas the paclitaxel was escalated in successive cohorts from 90 to 250 mg\/m<jats:sup>2<\/jats:sup>. Patients who had received previous radiotherapy to the whole pelvis were escalated separately from those who had not. <\/jats:p><jats:p> RESULTS: Eighty patients received 320 cycles of therapy. When G-CSF was not used, myelosuppression prevented escalation beyond the starting dose for patients with or without previous pelvic radiotherapy. When G-CSF was added, neurotoxicity became dose-limiting for both groups. Ten patients were removed from the study for asymptomatic declines in ejection fraction, but no symptomatic congestive heart failure was observed. Major antitumor responses occurred in 46% of patients (six of 13) with measurable endometrial carcinoma and 50% of patients (eight of 16) with measurable cervical carcinoma. <\/jats:p><jats:p> CONCLUSION: The combination of paclitaxel, doxorubicin, and cisplatin at relevant single-agent doses is active and feasible with the addition of G-CSF. A regimen of cisplatin 60 mg\/m<jats:sup>2<\/jats:sup>, doxorubicin 45 mg\/m<jats:sup>2<\/jats:sup>, and paclitaxel 160 mg\/m<jats:sup>2<\/jats:sup> with G-CSF support is recommended for further testing. <\/jats:p>","DOI":"10.1200\/jco.2001.19.4.1021","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:36:16Z","timestamp":1487918176000},"page":"1021-1029","source":"Crossref","is-referenced-by-count":51,"title":["Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group Study"],"prefix":"10.1200","volume":"19","author":[{"given":"Gini F.","family":"Fleming","sequence":"first","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Fowler","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Waggoner","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin E.","family":"Greer","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Horowitz","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Sutton","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison G.","family":"Ball","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"William P.","family":"McGuire","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Chicago, Chicago, IL; Ohio State University, James Cancer Hospital and Solove Research Institute, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbus, OH; Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA; Division of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA; Gynecologic Oncology, Indiana..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-085065","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.48.1.6"},{"key":"R2-085065","unstructured":"Thigpen  T,   Blessing  J,   Homesley  H,  et al:  Phase III trial of doxorubicin +\/- cisplatin in advanced or recurrent endometrial carcinoma:   A Gynecologic Oncology Group (GOG) study.   Proc Am Soc Clin Oncol 12:  261,1993  (abstr 830)"},{"key":"R3-085065","unstructured":"Aapro  M,   Bolis  G,   Chevallier  B,  et al:  An EORTC-GCCG randomized phase II trial of doxorubicin (dox) versus dox-cisplatin (CDDP) in endometrial carcinoma.   Proc Am Soc Clin Oncol 13:  275,1994  (abstr 885)"},{"key":"R4-085065","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0227"},{"key":"R5-085065","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010768"},{"key":"R6-085065","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199606000-00016"},{"key":"R7-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1617"},{"key":"R8-085065","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199312000-00007"},{"key":"R9-085065","unstructured":"Frassineti  GL,   Zoli  W,   Silvestro  L,  et al:  Paclitaxel plus doxorubicin in breast cancer:   An Italian experience.   Semin Oncol 24:  s17-19,1997\u2013s17-25,     (suppl 17)"},{"key":"R12-085065","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.1.13"},{"key":"R13-085065","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780111408"},{"key":"R14-085065","unstructured":"Balducci  L,   Parker  M,   Sexton  W,  et al:  Pharmacology of antineoplastic agents in the elderly patient.   Semin Oncol 16:  76,1989-84,"},{"key":"R15-085065","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199710010-00004"},{"key":"R16-085065","unstructured":"Egorin  MJ:   Cancer pharmacology in the elderly.   Semin Oncol 20:  43,1993-49,"},{"key":"R17-085065","unstructured":"Lipschitz  D:   Age-related declines in hematopoietic reserve capacity.   Semin Oncol 22:  3,1995-5,     (suppl 1)"},{"key":"R18-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"R19-085065","unstructured":"Mamounas  E,   Brown  A,   Smith  R,  et al:  Effect of Taxol duration of infusion in advanced breast cancer (ABC):   Results from a NSABP B-26 trial comparing 3- to 24-hr infusion of high-dose Taxol.   Proc Am Soc Clin Oncol 17:  101a,1998  (abstr 389)"},{"key":"R20-085065","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008344507482"},{"key":"R21-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2688"},{"key":"R22-085065","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010717"},{"key":"R23-085065","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.10.3585"},{"key":"R24-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1906"},{"key":"R25-085065","unstructured":"Dombernowsky  P,   Boesgaard  M,   Andersen  E,  et al:  Doxorubicin plus paclitaxel in advanced breast cancer.   Semin Oncol 24:  s17-15,1997\u2013s17-18,     (suppl 17)"},{"key":"R26-085065","unstructured":"Martin  M,   Lluch  A,   Ojeda  B,  et al:  Paclitaxel plus doxorubicin in metastatic breast cancer:   Preliminary analysis of cardiotoxicity.   Semin Oncol 24:  s17-26,1997\u2013s17-30,     (suppl 17)"},{"key":"R27-085065","unstructured":"Hortobagyi  GN,   Willey  J,   Rahman  Z,  et al:  Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.   Semin Oncol 24:  s17-65,1997\u2013s17-68,     (suppl 17)"},{"key":"R28-085065","unstructured":"Gianni  L,   Dombernowsky  P,   Sledge  G,  et al:  Cardiac function following combination therapy with Taxol (T) and doxorubicin (A) for advanced breast cancer.   Proc Am Soc Clin Oncol 17:  115a,1998  (abstr 444)"},{"key":"R29-085065","doi-asserted-by":"publisher","DOI":"10.3109\/07357909809039759"},{"key":"R30-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.11.1806"},{"key":"R31-085065","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(78)90011-5"},{"key":"R32-085065","unstructured":"Muss  HB:   Chemotherapy of metastatic endometrial cancer.   Semin Oncol 21:  107,1994-113,"},{"key":"R33-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.1071"},{"key":"R34-085065","unstructured":"Henderson  IC,   Berry  D,   Demetri  G,  et al:  Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC).   Proc Am Soc Clin Oncol 17:  101a,1998  (abstr 390A)"},{"key":"R35-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.1050"},{"key":"R36-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1066"},{"key":"R37-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2395"},{"key":"R38-085065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.46"},{"key":"R39-085065","doi-asserted-by":"crossref","unstructured":"Zanotti  KM,   Belison  JL,   Kennedy  AW,  et al:  The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.   Oncol 74:  272,1999-277,","DOI":"10.1006\/gyno.1999.5444"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.4.1021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:34:22Z","timestamp":1653514462000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.4.1021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,15]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,2,15]]}},"alternative-id":["10.1200\/JCO.2001.19.4.1021"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.4.1021","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,15]]}}}